|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||182.30 - 184.89|
|52-week range||182.30 - 184.89|
|Beta (5Y monthly)||1.10|
|PE ratio (TTM)||17.33|
|Earnings date||26 Oct 2021 - 01 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
PerkinElmer's (PKI) latest acquisition is likely to expand its life science business and enhance its reagents portfolio.
WALTHAM, Mass., September 17, 2021--PerkinElmer today announced it has completed its acquisition of BioLegend, a leading, worldwide provider of life science antibodies and reagents
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.